Ketamine Treatment

Developmental-stage psychedelics biotech company Silo Pharma Inc. (NASDAQ: SILO) has begun dosing in its IND-enabling study of proprietary time-released, topical formulation of ketamine SP-26 designed to treat fibromyalgia.  This safety evaluation trial will be conducted by Experimur, a...

Specialty biopharma company PharmaTher Holdings Ltd. (OTCQB: PHRRF) has entered into an evaluation and exclusive option agreement with Case Western Reserve University (CWRU) for the development and commercialization of the IP of ketamine for the treatment of the Rett Syndrome (RTS), a rare genetic...

The 100 Million Ways Foundation (100MW), a not-for-profit organization focused on harm reduction and improving quality of life of those with opioid use disorders, pulled in nearly $100,000 in fundraising at a recent gala commemorating the work carried out so far.  Co-founder and...

(Part three of a four-part series) As for ketamine-assisted therapy, biotech psychedelics company Awakn Life Sciences (OTC: AWAKNF) offers two distinct protocols. One is called KARE (Ketamine in the Reduction of Alcoholic Relapse) and is specific to alcohol use disorder, while the other, KAP (...

SEVALENT, Bexson Biomedical’s disrupting offer ready for the small molecule injectable market, received patent allowance by the USPTO for “Complexing Agent Salt Formulations of Pharmaceutical Compounds.”  The company’s formulation technology enables wearable, home...

The popular herbal supplement producer Irwin Naturals Inc. (OTC: IWINF) has acquired two additional ketamine clinics through the purchase of Invictus Clinics LLC’s assets. Irwin recently bought a ketamine clinic in New England. This time, the facilities are located in Atlanta and...

Myconic Capital Corp. (CNSX: MEDI) is poised to acquire a Victoria, British Columbia-based physical therapy clinic exclusively for the Canadian military, Royal Canadian Mounted Police (RCMP), and first responder patients. Transaction Details: The Vancouver-based investment company, which...

Myconic Capital Corp. (CSE: MEDI) agreed to buy Mindscape Ketamine & Infusions Therapy PLLC for $175,000. The investment company, which previously operating as Auralite Investments Inc. and has holdings in cannabis, signed a letter of intent to acquire all shares of Mindscape for...